Journal
CANCER BIOLOGY & THERAPY
Volume 14, Issue 1, Pages 45-55Publisher
TAYLOR & FRANCIS INC
DOI: 10.4161/cbt.22627
Keywords
-
Categories
Funding
- 973 National Key Fundamental Research Program of China [2009CB521801]
- National Natural Science Foundation of China [81071633, 81021061]
Ask authors/readers for more resources
The role of cyclin B1 in the clinical therapeutic sensitivity of human esophageal squamous cell carcinoma (ESCC) remains to be defined. In this study, we found that elevated cyclin B1 expression attenuated the apoptosis induced by cisplatin or paclitaxel, while knockdown of cyclin B1 enhanced cisplatin or paclitaxel sensitivity in ESCC cells. Cyclin B1-mediated apoptosis may rely on the Bcl-2-dependent mitochondria-regulated intrinsic death pathway, and the antagonizing effect of cyclin B1 on chemotherapeutic agent-induced apoptosis was through PTEN/Akt pathway. Therefore, cyclin B1 might be a therapeutic target for the development of specific and efficient approaches in the treatment of ESCC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available